研究单位：[1]Shandong Provincial Third Hospital[2]Shandong Qilu Stem Cells Engineering Co., Ltd.[3]Dezhou People's Hospital[4]Children's Hospital Affiliated to Shandong University[5]The Second Affiliated Hospital of Shandong First Medical University[6]Tai'an Central Hospital[7]Linyi People's Hospital[8]Linyi Central Hospital[9]Rizhao People's Hospital[10]Lanling People's Hospital[11]Jining First People's Hospital[12]The affiliated hospital of Jining medical college[13]Zibo municipal hospital[14]Binzhou People's Hospital[15]The Affiliated Hospital of Binzhou Medical College[16]Shengli Oilfield Central Hospital[17]Weihai Municipal Hospital[18]Weihai Central Hospital[19]The Second Affiliated Hospital of Shandong University of traditional Chinese Medicine[20]Gansu Provincial Hospital of Traditional Chinese Medicine (TCM)[21]Wuwei People's Hospital[22]Gansu Wuwei Tumour Hospital[23]The Second Affiliated Hospital of Harbin Medical University[24]Yuncheng Institute of Hematology[25]Kaifeng Central Hospital[26]Zhengzhou Central Hospital[27]Air Force Hospital of Western War Zone[28]The First People' s Hospital of Yunnan Province[29]Zigong No.1 Peoples Hospital[30]The First People's Hospital of Jingzhou[31]Jiangxi Province Children's Hospital[32]Second Affiliated Hospital of Zhengzhou University[33]Shandong University of Traditional Chinese Medicine[34]Yantai Ludong Hospital (Shandong Provincial Hospital Group)[35]Shandong Provincial Third Hospital,Jinan,Shandong,China,250031[36]Affiliated Hospital of Shandong University of Traditional Chinese Medicine,Jinan,Shandong,China[37]Jining first people's Hospital,Jining,Shandong,China[38]Linyi People's Hospital,Linyi,Shandong,China[39]Rizhao People's Hospital,Rizhao,Shandong,China[40]Tai'an Central Hospital,Tai'an,Shandong,China[41]Weihai Municipal Hospital,Weihai,Shandong,China[42]Yantai Ludong Hospital (Shandong Provincial Hospital Group),Yantai,Shandong,China
研究目的：
The multicenter collaborative clinical study conducted a systematic clinical observation in the treatment of bone marrow failure diseases via UCB&UC-MSCs , in order to observe its clinical efficacy and safety.
